What is OnKure Therapeutics, Inc.'s stock issuance proceeds?

OnKure Therapeutics, Inc. (OKUR) reported stock issuance proceeds of $1K in Q4 2024.

What is the long-term trend for OnKure Therapeutics, Inc.'s stock issuance proceeds?

Over 2 years (2021 to 2024), OnKure Therapeutics, Inc.'s stock issuance proceeds has grown at a -98.2% compound annual growth rate (CAGR), from $84.64M to $26K.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

OnKure Therapeutics, Inc. OKUR Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Eikon Therapeutics, Inc. EIKN

$277K+1,219%

Inhibrx Biosciences, Inc.INBX

$471K—

Replimune GroupREPL

$791K-99.3%

IDEAYA Biosciences, Inc.IDYA

$1.19M+4.9%

Erasca, Inc.ERAS

$258.75M+783,991%

Arcus BiosciencesRCUS

$0-100%

Other financials

Income statement

See full

Revenue-—

Operating income-$15.6M+8.1%

Net income-$15.2M+4.8%

EPS (diluted)-$1.11+6.7%

Balance sheet

See full

Cash & equivalents$192.1M+98.7%

Total debt$409.0K-57.2%

Total equity$184.4M+103%

Total assets$198.7M+98.9%

Cash flow

See full

Operating cash flow-$12.9M+7.6%

CapEx$5.0K-72.2%

Free cash flow-$12.9M+7.7%

Valuation

See full

Market cap$184.2M+72.6%

Enterprise value-$7.49M-127%

Returns & leverage

See full

Return on equity-42.7%—

Debt / equity0×0.0×

Current ratio13.8×+2.6×

Where this comes from

Reported directly by OnKure Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: OnKure Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about OnKure Therapeutics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OnKure Therapeutics, Inc.'s stock issuance proceeds?: OnKure Therapeutics, Inc. (OKUR) reported stock issuance proceeds of $1K in Q4 2024.
What is the long-term trend for OnKure Therapeutics, Inc.'s stock issuance proceeds?: Over 2 years (2021 to 2024), OnKure Therapeutics, Inc.'s stock issuance proceeds has grown at a -98.2% compound annual growth rate (CAGR), from $84.64M to $26K.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.